会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明授权
    • Method and system for frequency reuse in wireless relay scenario
    • 无线中继方案和频率复用方法
    • US09491767B2
    • 2016-11-08
    • US14234730
    • 2011-12-12
    • Yanlong WangYongyu ChangJie GaoYun Zhu
    • Yanlong WangYongyu ChangJie GaoYun Zhu
    • H04W72/04H04W16/04H04W84/04H04W74/08
    • H04W72/0486H04W16/04H04W74/0866H04W84/047
    • The disclosure provides a method for frequency reuse in a wireless relay scenario, wherein a center frequency spectrum, an edge frequency spectrum and a random access frequency spectrum are pre-allocated to a cell according to a scenario parameter in the cell; load conditions of all mobile stations (MSs) covered by each relay station (RS) in the cell is calculated and reported to a base station (BS); the BS allocates the random access frequency spectrum to an RS according to load conditions of all RSs and schedules MSs. The disclosure also provides a system for frequency reuse in a wireless relay scenario. With the method and system above, the frequency spectrum planning is configurable, the random access frequency spectrum is introduced, and both the load balancing and user fairness are taken into consideration, which improves the throughput at the edge of the cell, especially can increase the throughput for the users whose throughput ranks poorly.
    • 本公开提供了一种在无线中继场景中的频率重用的方法,其中根据小区中的场景参数将中心频谱,边缘频谱和随机接入频谱预先分配给小区; 计算小区中每个中继站(RS)覆盖的所有移动台(MS)的负载情况并将其报告给基站(BS); BS根据所有RS和时间表MS的负载条件向RS分配随机接入频谱。 本公开还提供了一种用于无线中继场景中的频率重用的系统。 通过上述方法和系统,可以配置频谱规划,引入随机接入频谱,同时考虑负载均衡和用户公平性,提高小区边缘吞吐量,特别是可以增加 吞吐量排名不佳的用户的吞吐量。
    • 8. 发明授权
    • Antiviral activity of bicyclic heterocycles
    • 双环杂环的抗病毒活性
    • US09193741B2
    • 2015-11-24
    • US13699258
    • 2011-05-20
    • Steven De JongheLing-Jie GaoPiet HerdewijnJean HermanMiyeon JangPieter LeyssenThierry LouatJohan NeytsChristophe PannecouqueBart Vanderhoydonck
    • Steven De JongheLing-Jie GaoPiet HerdewijnJean HermanMiyeon JangPieter LeyssenThierry LouatJohan NeytsChristophe PannecouqueBart Vanderhoydonck
    • A61K31/519C07D513/04A61K31/52A61K31/551
    • A61K31/551A61K31/519A61K31/52A61K31/5377C07D473/00C07D513/04Y02A50/385Y02A50/465
    • The present invention relates to compound of Formula I, II, III, or IV, and/or a pharmaceutical acceptable addition salt thereof and/or a stereoisomer thereof and/or a solvate thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R11, and R12 are as defined in the claim 1 or as described in detail in the description of the invention, and to the use of said compounds to treat or prevent viral infections and their use to manufacture a medicine to treat or prevent viral infections, particularly infections with RNA-viruses belonging to the family of the Retroviridae, the family of the Flaviviridae and the family of the Picornaviridae and more preferably infections with Human Immunodeficiency Virus 1 (HIV1), Human Immunodeficiency Virus 2 (HIV2), Hepatitis C virus (HCV), Dengue virus, and enteroviruses like Coxsackievirus, Rhinovirus and Poliovirus. The present invention also relates to pharmaceutical compositions of said compounds and the use of said pharmaceutical compositions to treat or prevent viral infections. The present invention further relates to the use of said compounds as biologically active ingredients, more specifically as medicaments for the treatment of viral disorders and pathologic conditions such as, but not limited to, viral infections with Human Immunodeficiency Virus 1 (HIV1), Human Immunodeficiency Virus 2 (HIV2), Hepatitis C virus (HCV), Dengue virus, and enteroviruses like Coxsackievirus, Rhinovirus and Poliovirus.
    • 本发明涉及式I,II,III或IV化合物和/或其药学上可接受的加成盐和/或其立体异构体和/或其溶剂合物,其中R1,R2,R3,R4,R5, R6,R7,R8,R9,R11和R12如权利要求1中所定义或如在本发明的描述中详细描述的,以及所述化合物用于治疗或预防病毒感染及其用于制造 治疗或预防病毒感染的药物,特别是属于逆转录病毒科的家族,微病毒科的家族和小核糖核酸病毒科家族的RNA病毒的感染,更优选人免疫缺陷病毒1(HIV1),人类免疫缺陷病毒2 (HIV2),丙型肝炎病毒(HCV),登革热病毒和诸如柯萨奇病毒,鼻病毒和脊髓灰质炎病毒的肠道病毒。 本发明还涉及所述化合物的药物组合物和所述药物组合物用于治疗或预防病毒感染的用途。 本发明还涉及所述化合物作为生物活性成分的用途,更具体地说,作为治疗病毒性病症和病理状况的药物,例如但不限于人免疫缺陷病毒1(HIV1),人类免疫缺陷病毒 病毒2(HIV2),丙型肝炎病毒(HCV),登革热病毒和诸如柯萨奇病毒,鼻病毒和脊髓灰质炎病毒的肠道病毒。